These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 22116552)
1. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Rao E; Jiang C; Ji M; Huang X; Iqbal J; Lenz G; Wright G; Staudt LM; Zhao Y; McKeithan TW; Chan WC; Fu K Leukemia; 2012 May; 26(5):1064-72. PubMed ID: 22116552 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227 [TBL] [Abstract][Full Text] [Related]
3. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Xia H; Ooi LL; Hui KM Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579 [TBL] [Abstract][Full Text] [Related]
5. Downregulated microRNA-32 expression induced by high glucose inhibits cell cycle progression via PTEN upregulation and Akt inactivation in bone marrow-derived mesenchymal stem cells. Zhu G; Chai J; Ma L; Duan H; Zhang H Biochem Biophys Res Commun; 2013 Apr; 433(4):526-31. PubMed ID: 23524257 [TBL] [Abstract][Full Text] [Related]
6. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240 [TBL] [Abstract][Full Text] [Related]
7. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498 [TBL] [Abstract][Full Text] [Related]
8. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance. Kim A; Seong KM; Kang HJ; Park S; Lee SS Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678 [TBL] [Abstract][Full Text] [Related]
10. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-486-5p targeting PTEN Protects Against Coronary Microembolization-Induced Cardiomyocyte Apoptosis in Rats by activating the PI3K/AKT pathway. Zhu HH; Wang XT; Sun YH; He WK; Liang JB; Mo BH; Li L Eur J Pharmacol; 2019 Jul; 855():244-251. PubMed ID: 31075240 [TBL] [Abstract][Full Text] [Related]
12. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389 [TBL] [Abstract][Full Text] [Related]
13. PI3K/AKT pathway activation in bladder carcinogenesis. Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582 [TBL] [Abstract][Full Text] [Related]
14. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679 [TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression. Yu D; Zhang Y; Chen G; Xie Y; Xu Z; Chang S; Hu L; Li B; Bu W; Wang Y; Xiao W; Sun X; Chang G; Gao L; Qiang S; Wu X; Zhu W; Shi J Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):782-792. PubMed ID: 29961897 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427 [TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Rudelius M; Pittaluga S; Nishizuka S; Pham TH; Fend F; Jaffe ES; Quintanilla-Martinez L; Raffeld M Blood; 2006 Sep; 108(5):1668-76. PubMed ID: 16645163 [TBL] [Abstract][Full Text] [Related]
18. MiR-21 inhibitor suppressed the progression of retinoblastoma via the modulation of PTEN/PI3K/AKT pathway. Gui F; Hong Z; You Z; Wu H; Zhang Y Cell Biol Int; 2016 Dec; 40(12):1294-1302. PubMed ID: 27600360 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-494 promotes cervical cancer proliferation through the regulation of PTEN. Yang YK; Xi WY; Xi RX; Li JY; Li Q; Gao YE Oncol Rep; 2015 May; 33(5):2393-401. PubMed ID: 25738254 [TBL] [Abstract][Full Text] [Related]
20. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]